PFIZER INC.

The FDA approved Cobenfy, a new antipsychotic medication for schizophrenia, developed by Karuna Therapeutics. Despite its efficacy in clinical trials, concerns about insurance coverage and high list price ($22,500/year) may limit patient access. Bristol Myers Squibb, which acquired Karuna, plans to expand Cobenfy's use to bipolar disorder and Alzheimer's agitation, with ongoing studies.

GLP-1 drugs like Ozempic and Mounjaro are gaining attention as blockbuster drugs face patent cliffs. These drugs, initially for diabetes, now show significant weight loss, positioning them as next-gen treatments. Competition is fierce, with Novo Nordisk and Eli Lilly leading, but other companies like Amgen, Roche, Pfizer, and AstraZeneca are entering the market. Expanding the conditions these drugs treat could influence insurance coverage. The snack industry may need to innovate as GLP-1 drugs reduce processed food consumption. The patent cliff threatens big pharma, but Medicare negotiations and biologic drugs offer strategies. Innovations like pill-form obesity drugs and mRNA cancer treatments are on the horizon. Oncology and immunology remain dominant, but obesity is emerging as a significant driver. Stock picks include Roche, mRNA companies, and Pfizer.

Jefferies maintains 'buy' on Pfizer but lowers price target from $35 to $33 due to Oxbryta's market withdrawal and EMA review, citing VOC and fatal event imbalances in studies.

Breast cancer treatment market employs various drugs, including chemotherapy, hormone therapies, targeted therapies, and immunotherapy. Market growth is driven by increased incidence, research advancements, early detection awareness, personalized medicine, and new drug classes. The market is projected to reach USD 49.2 billion by 2032, with major companies like Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sun Pharmaceutical, Pfizer, Teva Pharmaceutical, and AbbVie leading in innovation and geographical expansion.

The European Medicines Agency (EMA) called for the suspension of Pfizer's Oxbryta, a sickle cell disease treatment, due to increased risks of vaso-occlusive crises and higher mortality rates. Pfizer voluntarily withdrew Oxbryta from global markets, citing the drug's risks no longer outweighing its benefits.

Article sent to my@email.address. All fields required for multiple recipients; separate emails with a semicolon. Only subscribers can access full articles; others directed to abstracts.

The article discusses the importance of SSR (Server-Side Rendering) in modern web development, emphasizing its role in enhancing performance and user experience.

Researchers emphasize the need for new generation therapeutics in precision medicine, including gene therapy, personalized medicine, immunotherapy, and advanced biologics. India is focusing on precision medicine, gene editing with CRISPR, and biologics. Collaborative ecosystems and digital health integration are accelerating innovation. Global-Bio India 2024 highlighted the shift towards biologics, India's first home-grown CAR-T cell therapy for cancer, and advanced cancer treatments. PepAI algorithm for Duchenne muscular dystrophy and repurposing of drugs were also discussed.

The article discusses the implementation of a Server-Side Rendering (SSR) service entry in a web application, utilizing a specific JavaScript bundle for enhanced performance and user experience.